Karl Herholz

Prof. Karl Herholz

orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2007 in British Journal of Radiology
Verified
Journal Article
Closed access
KHKarl Herholz
Karl Herholz
SCS F Carter
S F Carter
MJM Jones
M Jones
Positron emission tomography (PET) is a well-established imaging modality. Measurement of regional cerebral glucose metabolism (rCMRglc) using PET and [18F]-2-fluoro-2-deoxy-d-glucose (FDG) has bec...

1 July 2011 in The Lancet Neurology
Verified
Journal Article
Closed access
KHKarl Herholz
Karl Herholz
KEKlaus Ebmeier
Klaus Ebmeier

1 November 2012 in Seminars in Nuclear Medicine
Verified
Journal Article
Closed access
KHKarl Herholz
Karl Herholz
KLKarl-Josef Langen
Karl-Josef Langen
CSChristiaan Schiepers
Christiaan Schiepers
JMJames M. Mountz
James M. Mountz

1 November 2010 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
KHKarl Herholz
Karl Herholz
Assessment of regional cerebral glucose metabolism by (18)F-2-fluoro-2-deoxy-D-glucose (FDG)-PET at resting state is a standard functional technique to assess cerebral function. Group studies identified significant regional metabolic impairment in asymptomatic individuals at increased risk for dementia. Substantial impairment of FDG uptake in temporoparietal association cortices emerges as a reliable predictor of rapid progression to dementia in mild cognitive impairment patients and could, therefore, serve as a biomarker for the diagnosis of prodromal Alzheimer's disease. Frontal and temporoparietal metabolic impairment is closely related to progression of disease in longitudinal studies, and multicenter studies suggest its utility as an outcome parameter to increase the efficiency of therapeutic trials.

1 February 2006 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
NGNorbert Galldiks
Norbert Galldiks
LKLutz W. Kracht
Lutz W. Kracht
LBLothar Burghaus
Lothar Burghaus
ATAnne Thomas
Anne Thomas
AJAndreas H. Jacobs
Andreas H. Jacobs
KHKarl Herholz
Karl Herholz

15 July 2011 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
KHKarl Herholz
Karl Herholz
SWSarah Westwood
Sarah Westwood
CHCathleen Haense
Cathleen Haense
GDGraham Dunn
Graham Dunn
Increasingly, clinical trials are being planned in patients with mild cognitive impairment (MCI) to prevent or delay the onset of dementia in Alzheimer disease (AD) by disease-modifying intervention. Inclusion of imaging techniques as biomarkers for patient selection and assessment of outcome is expected to increase trial efficacy. PET using 18F-FDG provides objective information about the impairment of synaptic function and could, with appropriate standardization, qualify as a biomarker. Methods: We evaluated a predefined quantitative measure (PET score) that is extracted automatically from 18F-FDG PET scans using a sample of controls (n = 44), patients with MCI (n = 94), and patients with mild AD (n = 40) from the Alzheimer Disease Neuroimaging Initiative (ADNI). Subjects received 4 scans and clinical assessments over 2 y. Results: PET scores provide much higher test–retest reliability than standard neuropsychologic test scores (Alzheimer's Disease Assessment Scale–Cognitive [ADAS-cog] and Mini-Mental State Examination) and superior signal strength for measuring progression. At the same time, they are related linearly to ADAS-cog scores, thus providing a valid measure of cognitive impairment. In addition, PET scores at study entry in MCI patients significantly predict clinical progression to dementia with a higher accuracy than Mini-Mental State Examination and ADAS-cog. Conclusion: 18F-FDG PET scores are a valid imaging biomarker to monitor the progression of MCI to AD. Their superior test–retest reliability and signal strength will allow the reduction in the number of subjects needed or shortening of study duration substantially.